title: Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
authors: Hospital São João and Faculty of Medicine of Porto and Instituto de Investigação e Inovação em Saúde (I3S), Porto, Portugal. Electronic address: cruzfjmr@med.up.pt.
authors: Francisco
authors: F
authors: Cruz
mesh_terms: D000083:Acetanilides; D004311:Double-Blind Method; D006801:Humans; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines; D013844:Thiazoles; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive
chemical_list: D000083:Acetanilides; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D013844:Thiazoles; D000069464:Solifenacin Succinate; C520025:mirabegron